Health Discovery Corporation announces approval of patent application covering Fractal Genomics Modelling (FGM) technology

Savannah 28 March 2005Health Discovery Corporation has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application covering "The method for the manipulation, storage, modelling, visualization and quantification of datasets using a proprietary adaptation of the fractal analysis". This is the base patent application and the first of a series of patent applications covering the Fractal Genomics Modelling (FGM) technology. The FGM technology can be applied to genomic analysis to identify biomarkers to develop treatments, diagnoses or prognoses of diseases by exploiting the map of interactions and the causal relationships between genes rendered by this technology.


In addition to this allowed patent application for its Fractal Genomics Modelling (FGM) technology, Health Discovery Corporation's patent portfolio includes 10 issued United States and foreign patents covering among other things applications of its support vector machine (SVM) technology and Recursive Feature Elimination (RFE) technology used in Support Vector Machines for biomarker discovery.

The issued patents cover methods and systems for pre-processing data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet while collecting financial compensation electronically in the process.

In addition, Health Discovery Corporation has over 65 pending patent applications for various techniques used in biomarker discovery as well as for newly discovered biomarkers. HDC's pending United States and foreign patent applications cover numerous improvements to and applications of FGM techniques and SVM techniques, including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images of digital mammography for breast cancer and images of blood for the identification of circulating tumour cells, methods of feature selection for enhanced SVM efficiency and new biomarkers discovered for colon cancer, prostate cancer, leukemia and renal cancer using these methods, as well as the use of SVMs for analysis of spectral data such as data generated in mass spectrometry.

The original scientific publication introducing Recursive Feature Elimination (RFE) in Support Vector Machines (SVMs) was co-authored by Health Discovery Corporation's Chairman and CEO, Dr. Stephen D. Barnhill, and two members of Health Discovery Corporation's Scientific Team: Dr. Vladimir Vapnik and Dr. Isabelle Guyon.

Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, commented: "I am thrilled that the United States Patent and Trademark Office has issued a Notice of Allowance for the first in a series of patent applications covering our Fractal Genomics Modelling (FGM) technology which has been shown to be a very important tool for proteomic and genomic biomarker discovery. FGM is a great addition to the company's patented Support Vector Machine technology which is also critical to our biomarker discovery efforts."

Dr. Barnhill continued: "This Notice of Allowance further solidifies our position as a leader in biomarker discovery, which is considered to be a very important aspect of the personalized medicine process recently described in the Food and Drug Administration (FDA) final guidance titled Pharmacogenomic Data Submissions released March 22, 2005, as part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics."

Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA, explained that "personalized medical treatment" is now one step closer, further stating: "This new technology will allow medicines to be uniquely crafted to maximize their therapeutic benefits and minimize their potential risks for each patient."

The FDA's Press Release stated: "Instead of the standard hit-or-miss approach to treating patients, where it can take multiple attempts to find the right drug and the right dose, doctors will eventually be able to analyse a patient's genetic profile and prescribe the best available drug therapy and dose from the start. Both the guidance and a new Web page are part of a broad effort underway at FDA to foster pharmacogenomics during drug development."

"We hope ultimately to bring pharmacogenomics, a way in which to foster the personalizing of medicine, to every health care professional's prescription pad for the benefit of their patients and United States consumers", stated Dr. Woodcock.

Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery. The company was established to provide pharmaceutical and diagnostic companies worldwide with newly discovered biomarkers used to create more accurate diagnostic tests, novel drug targets for more personalized medicines and new methods for detecting patients "at-risk" for toxicity-related events, thereby providing safer medications. Founded in September 2003, the company is headquartered in Savannah, Georgia.

More information about Health Discovery Corporation's technology can be found in the original paper on Recursive Feature Elimination (RFE) in Support Vector Machines (SVMs). More details on the FDA Guidance for Industry can be read in "Pharmacogenomic Data Submissions" released on March 22, 2005.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]